A Study of Tucatinib and Trastuzumab in People With Rectal Cancer
Status:
Recruiting
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
The study researchers believe that a combination of the drugs trastuzumab and tucatinib,
given with standard chemotherapy (capecitabine and oxaliplatin/CAPOX), may help participants
with rectal cancer.